Oral Anticoagulation Clinical Trial
— ECLIPSE-02Verified date | February 2013 |
Source | Biosite |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
This multi-center study is designed to evaluate the ability of intended lay users (patients on oral anticoagulation therapy, OAT, or their caregivers) to 1) operate the INRatio Prothrombin Time (PT) Monitoring System utilizing the INRatio test strip newly designed for low sample volume and heparin insensitivity, and 2) obtain accurate results for the quantitative determination of International Normalized Ratio (INR) when self-testing using fingerstick capillary blood. Patients will be trained by their healthcare provider using the instructions for use and product labeling provided. The accuracy of the patient INR results will be assessed by comparison to the INR results obtained by the site's trained healthcare professional using the same INRatio system (from a separate fingerstick collected from the same patient at the point-of-care), and with the INR results obtained on venous plasma obtained from the same patient and analyzed at a central laboratory with the Sysmex CA-560 System INR reference method.
Status | Completed |
Enrollment | 183 |
Est. completion date | September 2010 |
Est. primary completion date | June 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adults (18 years of age or older); - Ability to read and speak English; - Subjects on stable oral anticoagulation therapy with warfarin (at least 3 months); - Target INR interval between 2.0 and 4.5 - Willing and able to provide written informed consent and comply with study procedures; Exclusion Criteria: - Hematocrit less than 25 or greater than 55% - Lupus or antiphospholipid syndrome (APS) - Already participated in this study - A current INRatio PT Monitoring System User / Patient Self Tester |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Fox Valley Cardiology | Aurora | Illinois |
United States | Loma Linda VA Hospital | Loma Linda | California |
United States | UC Davis Healthcare System | Sacramento | California |
United States | San Diego Cardiac Center | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
Biosite |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Operate the INRatio Prothrombin Time (PT) Monitoring System utilizing the INRatio test strip newly designed for low sample volume and heparin insensitivity. | 8 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00603317 -
Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid
|
Phase 4 | |
Completed |
NCT02533960 -
Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime
|
||
Completed |
NCT00596570 -
Management of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting
|
N/A | |
Not yet recruiting |
NCT05723926 -
Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
|
N/A | |
Recruiting |
NCT05955365 -
Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation
|
Phase 4 | |
Completed |
NCT02067182 -
Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation
|
Phase 4 | |
Completed |
NCT04307225 -
Atrial Fibrillation After CABG and PCI
|